Verve Therapeutics (VERV) Guggenheim Securities Inaugural Healthcare Innovation Conference summary

Strategic vision and innovation

• Developing one-time gene editing therapies for lifelong cholesterol reduction, aiming to prevent heart attacks based on genetic insights from 2018.

• Pipeline targets three axes of lipid risk: LDL, triglyceride-rich lipoproteins, and lipoprotein(a), with a product for each.

• Focus on addressing poor adherence to current lifelong therapies by offering a single-dose solution.

Clinical progress and pipeline updates

• Three clinical programs: VERVE-101 and VERVE-102 (targeting PCSK9), VERVE-201 (ANGPTL3), and a program for lipoprotein(a).

• VERVE-102 uses a new GalNAc lipid nanoparticle delivery system to improve safety and efficacy, with initial data expected in the first half of 2025.

• VERVE-101 showed durable LDL reduction but had transient safety issues attributed to its delivery system.

• VERVE-201 targets patients with homozygous FH and refractory hypercholesterolemia, with data expected next year.

Safety, efficacy, and patient selection

• VERVE-101 demonstrated 57% LDL reduction sustained for 18 months, with safety issues limited to the acute post-dosing period.

• VERVE-102 aims to maintain efficacy while reducing safety concerns by using a different delivery system.

• Patient selection for Heart-2 trial now focuses on those with moderate disease, excluding severe blockages to minimize confounding safety risks.